1. Transposon-sequencing (Tn-seq) of the Candida glabrata reference strain CBS138 reveals epigenetic plasticity, structural variation, and intrinsic mechanisms of resistance to micafungin.
- Author
-
Nickels TJ, Gale AN, Harrington AA, Timp W, and Cunningham KW
- Subjects
- Genetic Variation, Genome, Fungal, Fungal Proteins genetics, Fungal Proteins metabolism, Candida glabrata drug effects, Candida glabrata genetics, Micafungin pharmacology, DNA Transposable Elements, Drug Resistance, Fungal genetics, Epigenesis, Genetic, Antifungal Agents pharmacology
- Abstract
Candida glabrata (also called Nakaseomyces glabratus) is an opportunistic pathogen that can resist common antifungals and rapidly acquire multidrug resistance. A large amount of genetic variation exists between isolates, which complicates generalizations. Portable transposon-sequencing (Tn-seq) methods can efficiently provide genome-wide information on strain differences and genetic mechanisms. Using the Hermes transposon, the CBS138 reference strain and a commonly studied derivative termed 2001 were subjected to Tn-seq in control conditions and after exposure to varying doses of the clinical antifungal micafungin. The approach revealed large differences between these strains, including a 131-kb tandem duplication and a variety of fitness differences. Additionally, both strains exhibited up to 1,000-fold increased transposon accessibility in subtelomeric regions relative to the BG2 strain, indicative of open subtelomeric chromatin in these isolates and large epigenetic variation within the species. Unexpectedly, the Pdr1 transcription factor conferred resistance to micafungin through targets other than CDR1. Other micafungin resistance pathways were also revealed including mannosyltransferase activity and biosynthesis of the lipid precursor sphingosine, the inhibition of which by SDZ 90-215 and myriocin enhanced the potency of micafungin in vitro. These findings provide insights into the complexity of the C. glabrata species as well as strategies for improving antifungal efficacy., Competing Interests: Conflicts of interest The authors declare no conflicts of interest., (Published by Oxford University Press on behalf of The Genetics Society of America 2024.)
- Published
- 2024
- Full Text
- View/download PDF